Russell Investments Group Ltd. boosted its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 0.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 196,998 shares of the life sciences company’s stock after acquiring an additional 1,041 shares during the period. Russell Investments Group Ltd. owned 0.25% of Integra Lifesciences worth $10,902,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. Deutsche Bank AG increased its position in Integra Lifesciences by 13.1% during the 4th quarter. Deutsche Bank AG now owns 289,188 shares of the life sciences company’s stock worth $13,838,000 after buying an additional 33,598 shares during the period. Gotham Asset Management LLC bought a new position in Integra Lifesciences during the 4th quarter worth $3,453,000. Swiss National Bank increased its position in Integra Lifesciences by 6.4% during the 4th quarter. Swiss National Bank now owns 106,394 shares of the life sciences company’s stock worth $5,092,000 after buying an additional 6,400 shares during the period. Geode Capital Management LLC increased its position in Integra Lifesciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 563,397 shares of the life sciences company’s stock worth $26,964,000 after buying an additional 2,579 shares during the period. Finally, Sei Investments Co. increased its position in Integra Lifesciences by 3.8% during the 4th quarter. Sei Investments Co. now owns 184,244 shares of the life sciences company’s stock worth $8,818,000 after buying an additional 6,719 shares during the period. Hedge funds and other institutional investors own 79.49% of the company’s stock.
Several research firms have weighed in on IART. ValuEngine upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Friday, April 27th. Oppenheimer set a $70.00 target price on Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, May 1st. BidaskClub raised Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Thursday, March 15th. JPMorgan Chase & Co. increased their target price on Integra Lifesciences from $55.00 to $57.00 and gave the stock a “neutral” rating in a report on Thursday, April 26th. Finally, JMP Securities increased their target price on Integra Lifesciences from $57.00 to $60.00 and gave the stock a “market outperform” rating in a report on Wednesday, February 28th. Eleven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Integra Lifesciences presently has a consensus rating of “Hold” and an average target price of $60.69.
In related news, VP Daniel L. Reuvers sold 1,000 shares of Integra Lifesciences stock in a transaction on Monday, April 30th. The stock was sold at an average price of $62.04, for a total transaction of $62,040.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.
NASDAQ:IART opened at $67.23 on Monday. The stock has a market capitalization of $5.91 billion, a P/E ratio of 34.65, a price-to-earnings-growth ratio of 2.02 and a beta of 0.65. The company has a current ratio of 2.53, a quick ratio of 1.66 and a debt-to-equity ratio of 1.77. Integra Lifesciences Holdings Corp has a twelve month low of $41.51 and a twelve month high of $67.41.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.09. The company had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $349.15 million. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. Integra Lifesciences’s quarterly revenue was up 38.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 earnings per share. equities analysts predict that Integra Lifesciences Holdings Corp will post 2.41 EPS for the current fiscal year.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.